GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biomarin Pharmaceutical Inc (LTS:0HNC) » Definitions » Institutional Ownership

Biomarin Pharmaceutical (LTS:0HNC) Institutional Ownership : 75.80% (As of Apr. 19, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Biomarin Pharmaceutical Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Biomarin Pharmaceutical's institutional ownership is 75.80%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Biomarin Pharmaceutical's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Biomarin Pharmaceutical's Float Percentage Of Total Shares Outstanding is 98.80%.


Biomarin Pharmaceutical Institutional Ownership Historical Data

The historical data trend for Biomarin Pharmaceutical's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biomarin Pharmaceutical Institutional Ownership Chart

Biomarin Pharmaceutical Historical Data

The historical data trend for Biomarin Pharmaceutical can be seen below:

2024-06-30 2024-07-31 2024-08-31 2024-09-30 2024-10-31 2024-11-30 2024-12-31 2025-01-31 2025-02-28 2025-03-31
Institutional Ownership 76.39 75.34 75.79 75.24 75.28 74.50 76.97 76.27 76.43 75.80

Biomarin Pharmaceutical Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Biomarin Pharmaceutical Business Description

Address
770 Lindaro Street, San Rafael, CA, USA, 94901
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.

Biomarin Pharmaceutical Headlines

No Headlines